Curbside Consultation in IBD
49 Clinical Questions
Series: Curbside Consultation in Gastroenterology;
- Publisher's listprice GBP 105.00
-
50 163 Ft (47 775 Ft + 5% VAT)
The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.
- Discount 20% (cc. 10 033 Ft off)
- Discounted price 40 131 Ft (38 220 Ft + 5% VAT)
Subcribe now and take benefit of a favourable price.
Subscribe
50 163 Ft
Availability
Estimated delivery time: In stock at the publisher, but not at Prospero's office. Delivery time approx. 3-5 weeks.
Not in stock at Prospero.
Why don't you give exact delivery time?
Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.
Product details:
- Edition number 3, New edition
- Publisher CRC Press
- Date of Publication 15 October 2021
- Number of Volumes Paperback
- ISBN 9781630916503
- Binding Paperback
- No. of pages376 pages
- Size 254x178 mm
- Weight 907 g
- Language English 204
Categories
Short description:
Newly updated with the latest information on inflammatory bowel disease, Curbside Consultation in IBD: 49 Clinical Questions, Third Edition contains brief, practical, and evidence-based answers to the most frequently asked questions that are posed during a “curbside consultation” between surgical colleagues.
MoreLong description:
Newly updated with the latest information on inflammatory bowel disease, Curbside Consultation in IBD: 49 Clinical Questions, Third Edition contains brief, practical, and evidence-based answers to the most frequently asked questions that are posed during a “curbside consultation” between surgical colleagues.&&&160;
Drs. David T. Rubin, Sonia Friedman, and Francis A. Farraye are joined by an expert group of contributors, offering advice, preferences, and opinions on tough clinical questions commonly associated with IBD. With a unique Q&A format, this text provides quick access to current information. Numerous images, diagrams, and references are included to better illustrate IBD.
Some of the questions answered inside the Third Edition include:
- What are the new approaches to using and minimizing steroids? &&&160;
- What is the evolving role of calcineurin inhibitors in IBD? &&&160;
- Where should anti-IL-23 therapy be placed in the therapeutic algorithm for Crohn’s disease and ulcerative colitis?
- What should the clinicians and patients know about biosimilars? &&&160;
- What are JAK inhibitors? And when should they be used in IBD? &&&160;
- What is the approach to loss of response to biological therapy? &&&160;
- How should we screen our patients with IBD for depression and anxiety?
Table of Contents:
Dedication About the Editors Contributing Authors Preface Introduction Section I Diagnosis and Prognosis Question 1 How Can We Assess Prognosis in Crohn's Disease? Carolina Palmela, MD and Joana Torres, MD, PhDQuestion 2 How Do You Evaluate and Treat Mid-Proximal Small BowelCrohn's Disease? Jean A. Donet, MD and Mark Lazarev, MDQuestion 3 What Is Your First-Line Approach to the Diagnosis andTreatment of Patients With Perianal Crohn's Disease? Baldeep S. Pabla, MD, MSCI and David A. Schwartz, MDQuestion 4 What Is the Updated Role of Capsule Endoscopy in IBD? Shabana F. Pasha, MD and Jonathan A. Leighton, MDQuestion 5 How Should We Be Using Fecal Markers in Our Patients? Anthony Buisson, MD, PhD and David T. Rubin, MDQuestion 6 What Endpoints Should We Aim for in IBD Medical Therapy? Maia Kayal, MD and Jean-Frederic Colombel, MD Section II Medical Treatment Question 7 When Should We Be Using 5-Aminosalicylic Acids in IBD?How Do You Optimize Their Use? Stephen B. Hanauer, MD and Madeline Bertha, MDQuestion 8 What Is Steroid Dependence and How Is It Managed? David B. Sachar, MDQuestion 9 What Are the New Approaches to Using and Minimizing Steroids? Irving Levine, MD and Brian P. Bosworth, MDQuestion 10 Should You Use Concomitant Immunomodulators With BiologicalTherapies in IBD? Remo Panaccione, MDQuestion 11 If, When, and How Should Thiopurines Be Used in IBD? Jennie Clough, MBBS and Peter M. Irving, MBBS, MA, MDQuestion 12 How Should Methotrexate Be Used in IBD? Hans Herfarth, MD, PhD and Edward L. Barnes, MD, MPHQuestion 13 What Is the Evolving Role of Calcineurin Inhibitors in IBD? Ralley Prentice, MBBS and Britt Christensen, BSc, MBBS (Hons), MPH, PhDQuestion 14 What Preparations Should Occur Before Initiating Biologic Therapy? Akriti P. Saxena, MD and Mark T. Osterman, MD, MSCEQuestion 15 Where Should Anti-Integrin Therapy Be Placed in the TherapeuticAlgorithm for Crohn's Disease and Ulcerative Colitis? Rachel W. Winter, MD, MPH and Sonia Friedman, MDQuestion 16 Where Should Anti–Interleukin 23 Therapy Be Placed in the TherapeuticAlgorithm for Crohn's Disease and Ulcerative Colitis? Joel Pekow, MDQuestion 17 What Should Clinicians and Patients Know About Biosimilars? Ferdinando D'Amico, MD, PhD and Silvio Danese, MD, PhDQuestion 18 What Are Janus Kinase Inhibitors andWhen Should They Be Used in IBD? Roni Weisshof, MD and David T. Rubin, MDQuestion 19 What Is the Approach for Loss of Response to Biological Therapy? Konstantinos Papamichael, MD, PhD and Adam Cheifetz, MDQuestion 20 How Should Proactive Therapeutic Drug Monitoring Be Considered inOur Patients? Joseph D. Feuerstein, MD and William T. Clarke, MD, MScQuestion 21 What Are the Risks of Biologic Therapies and How Do YouCommunicate Them to Patients? Susan Connor, MBBS (Hons 1), B Med Sci, PhD and Yang (Clare) Wu, MBChBQuestion 22 When Should We Consider Deescalation of Therapy? Seth R. Shaffer, MD, MS and David T. Rubin, MDQuestion 23 Can You Restart a Biological Therapy After a Drug Holiday?How Do You Do This? Filip J. Baert, MD, PhD and David Drobne, MD, PhDQuestion 24 How Can I Get My Patients With IBD the Therapy They Need? Shivani A. Patel, PharmD, BCPS and Toni M. Zahorian, PharmD, BCACP Section III Alternative Treatments Question 25 What Is the Role of Probiotics for Patients With IBD? Kerri Glassner, DO and Bincy P. Abraham, MD, MSQuestion 26 What Do I Tell My Patient With IBD Who Is Asking AboutCannabis as Therapy? Jami Kinnucan, MD and Arun Swaminath, MD Section IV Special Populations Question 27 How Do You Treat Pouchitis and What Do You Do for Recurrent orRefractory Pouchitis? Iris Dotan, MD and Idan Goren, MDQuestion 28 My Patient With IBD Is Complaining of Joint Pain. What Should I Do? Abha G. Singh, MD and Arthur Kavanaugh, MDQuestion 29 What Are the Diagnostic and Therapeutic Approaches to thePatient With IBD With Pain? Emily Weaver, LCSW and Eva Szigethy, MD, PhDQuestion 30 My Patient on Tumor Necrosis Factor Alpha Therapy Has a Rash.What Should I Do? Oluwakemi Onajin, MD and Diana Bolotin, MD, PhDQuestion 31 What Is the Approach to Primary Sclerosing Cholangitis in IBD? Bilal Hameed, MD and Norah Terrault, MD, MPHQuestion 32 What Is the Best Medical Therapy for IBD in Older Patients? Seymour Katz, MDQuestion 33 How Should Clinicians Treat Men With IBD? What Are theUnique Concerns? Aoibhlinn O'Toole, MD and Sonia Friedman, MDQuestion 34 What Is the Updated Approach to IBD Medical Therapy in Pregnancy and What Is Known About Neonatal Outcomes in Babies Bornto Mothers With IBD? Muhammad Bader Hammami, MD and Uma Mahadevan, MD Section V Infection and Malignancy Prevention Question 35 How Do You Handle a Patient With IBDWith Clostridioides difficile Infection? Alexander N. Levy, MD and Jessica R. Allegretti, MD, MPHQuestion 36 How Do You Treat IBD in the Setting of Current or Previous Cancer? Steven H. Itzkowitz, MD and Jordan E. Axelrad, MD, MPHQuestion 37 What Is the Updated Approach to Surveillance and Colorectal CancerPrevention in IBD? Jimmy K. Limdi, MBBS and Francis A. Farraye, MD, MSc Section VI Surgical Treatment Question 38 What Is the Appropriate Evaluation of the PreoperativePatient With IBD? (Malnutrition, Steroids, Smoking) Amy L. Lightner, MDQuestion 39 My Patient With Crohn's Disease Has an Ileal Abscess.What Is the Appropriate Management and Timing of Medical andSurgical Therapies? Victor G. Chedid, MD, MSc and Sunanda V. Kane, MD, MSPHQuestion 40 What Is the Updated Approach to Monitoring and Prevention in aPatient With Crohn's Disease After an Ileocecectomy andPrimary Anastomosis? Ashwin N. Ananthakrishnan, MD, MPHQuestion 41 How Does Perioperative Immune Suppression Affect Surgical Outcomesin IBD? Shintaro Akiyama, MD, PhD; Akihiro Yamada, MD, PhD; andAtsushi Sakuraba, MD, PhDQuestion 42 Does the Type of Surgical Anastomosis (End-to-End Versus Side-to-Side)Make a Difference in Long-Term Crohn's Disease Outcomes andin Recurrence? Jana G. Hashash, MD, MSc; Andrew R. Watson, MD, MLitt; andDavid G. Binion, MD Section VII Health Maintenance Question 43 What Is the Most Successful Strategy to Promote Smoking Cessationin Patients With Crohn's Disease? Michael Buie, BHSc and Gilaad G. Kaplan, MD, MPHQuestion 44 Which Vaccines Should Patients With IBD Receive? Freddy Caldera, DO, MS and Francis A. Farraye, MD, MScQuestion 45 How Can Gastroenterologists Address IBD-Related Health Maintenance in Clinical Practice? Erica R. Cohen, MD and Gil Y. Melmed, MD, MSQuestion 46 How Should We Screen Our Patients With IBD forDepression and Anxiety? Alyse Bedell, PhD and Laurie Keefer, PhDQuestion 47 What Is the Role of Diet in the Treatment of IBD and How Do I Discuss This With My Patients? James D. Lewis, MD, MSCE and Tamar Pfeffer Gik, RD, MScQuestion 48 What Advice Should I Give the Patient With IBD Who Is Traveling? Kay Greveson, BA, MSc and Shomron Ben-Horin, MDQuestion 49 How Should We Approach the Diagnosis and Evaluation ofSexual Dysfunction in Patients With IBD? Punyanganie S. de Silva, MBBS, MPH and Sonia Friedman, MDFinancial Disclosures Index
More
How to Succeed with People ? Remarkably Easy Ways to Engage, Influence and Motivate Almost Anyone: Remarkably easy ways to engage, influence and motivate almost anyone
6 688 HUF
6 020 HUF